CAI vs FDMT

For growth investors, 4D Molecular Therapeutics, Inc.

(FDMT) is the stronger pick with 2302% revenue growth year-over-year, versus 97. 0% for Caris Life Sciences, Inc. (CAI). Analysts rate Caris Life Sciences, Inc. (CAI) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Caris Life Sciences, Inc.

(CAI) delivered a total return of -29. 1%, compared to -69. 7% for 4D Molecular Therapeutics, Inc. (FDMT). Over 10 years, the gap is even starker: CAI returned -29. 1% versus FDMT's -75. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), 4D Molecular Therapeutics, Inc.

(FDMT) is the lower-risk stock at 1. 47β versus Caris Life Sciences, Inc. 's 1. 60β — meaning CAI is approximately 8% more volatile than FDMT relative to the S&P 500. On balance sheet safety, 4D Molecular Therapeutics, Inc. (FDMT) carries a lower debt/equity ratio of 4% versus 66% for Caris Life Sciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), 4D Molecular Therapeutics, Inc.

(FDMT) is pulling ahead at 2302% versus 97. 0% for Caris Life Sciences, Inc. (CAI). On earnings-per-share growth, the picture is similar: Caris Life Sciences, Inc. grew EPS 29. 6% year-over-year, compared to 18. 8% for 4D Molecular Therapeutics, Inc.. Over a 3-year CAGR, FDMT leads at 200. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Caris Life Sciences, Inc.

(CAI) is the more profitable company, earning -66. 2% net margin versus -164. 4% for 4D Molecular Therapeutics, Inc. — meaning it keeps -66. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CAI leads at 5. 6% versus -187. 2% for FDMT. At the gross margin level — before operating expenses — FDMT leads at 91. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for FDMT: 232.

3% to $33. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, 4D Molecular Therapeutics, Inc.

(FDMT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Caris Life Sciences, Inc. (CAI) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FDMT: -75. 5%, CAI: -29. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.